Novel set of biomarkers useful for predicting lung cancer survival

FIELD OF THE INVENTION

The present invention is in the field of biomarkers and therapeutic targets.

BACKGROUND OF THE INVENTION

Lung cancer is the leading cause of cancer-related death worldwide [1], where non-small cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs with adenocarcinoma being the most common subtype. Microarray and next generation sequencing technologies have become invaluable tools to deconvolute the genetic heterogeneity and complexity of NSCLC, providing tremendous information to define new biomarkers for diagnosis, prognosis and prediction of therapeutic response, and to identify new potential therapeutic targets. Despite the advances in our knowledge of the genetic factors underlying this disease, the five-year survival rate for NSCLC patients is approximately 21% [2]. Lung cancer treatment is therefore moving rapidly towards an era of personalized medicine, where the molecular characteristics of an individual patient's tumor will dictate the optimal treatment modalities. For example, NSCLC patients with EGFR mutations show significantly improved responses to treatment with tyrosine kinase inhibitors, e.g., gefitinib or erlotinib, which target this protein [3].

Patient stratification based on histopathological markers, immunohistochemistry and other molecular factors has been evaluated to improve treatment decisions in LuADC patients [4-6]. The availability of large cancer genomic data sets allows for unbiased approaches to identify multi-gene signatures important in tumor progression. Gene transcript based signatures that predict prognosis have successfully been developed for many different tumor types [7-10]. A number of gene signatures using microarray analysis show promise for prognosis or prediction of response to therapy in NSCLC [11-14]. However, these signatures were either based on incomplete genome annotation or were based solely on existing knowledge. Therefore, a new comprehensive and unbiased genome-wide screening for genes associated with lung cancer prognosis is warranted.

SUMMARY OF THE INVENTION

The present invention provides for a library or an array of nucleic acids or nucleotides encoding portions of two or more genes selected from a set of 27 genes as indicated in Table 1 which are useful for predicting lung cancer survival.

In some embodiments, the library or the array of nucleic acids or nucleotides encoding portions of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or more, or all, genes selected from the set of 27 genes as indicated in Table 1. In some embodiments, the lung cancer is lung adenocarcinoma (LuADC).

The present invention also provides for a method for predicting a subject's overall survival (OS) from a lung cancer, comprising: (a) obtaining a lung gene transcript sample from a subject, (b) determining the transcript level of two or more genes selected from a set of 27 genes as indicated in Table 1, (c) correlating the pattern of the transcript to a predicted OS based on the analysis described herein, and (d) optionally treating the subject with a treatment regime appropriate to the predicted OS of the subject obtained from the correlating step.

In some embodiments, the determining step comprises determining the transcript level of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or more, or all, genes selected from the set of 27 genes as indicated in Table 1. In some embodiments, the subject is a person suspected of having a lung cancer, a person with a high probability of having a lung cancer, or a person diagnosed with a lung cancer. In some embodiments, the lung cancer is lung adenocarcinoma (LuADC). In some embodiments, the treatment comprises one or more of surgery, radiation therapy, and/or chemotherapy.

In some embodiments, the treatment regime is surgery radiation therapy, chemotherapy, targeted therapy, administering angiogenesis inhibitor, or immunotherapy. In some embodiments, the surgery is a lobectomy, wedge resection, segmentectomy, pneumoectomy, or sleeve resection. In some embodiments, the chemotherapy comprises administering to the subject of a therapeutic amount of (i) cisplatin or carboplatin, and (ii) pemetrexed or doctataxel. In some embodiments, the targeted therapy comprises administering to the subject of a therapeutic amount of (i) Crizotinib (Xalkori®), (ii) Ceritinib (Zykadia®), (iii) Alectinib (Alecensa®), and/or (iv) Brigatinib (Alunbrig™). Brigatinib (Alunbrig™) is administered to subjects whose cancer has grown while they were on Crizotinib or are intolerant to Crizotinib. In some embodiments, the targeted therapy comprises administering to the subject of a therapeutic amount of (i) Afatinib (Gilotrif®), (ii) Dacomitinib (Visimpro®), (iii) Erlotinib (Tarceva®), (iv) Gefitinib (Iressa®), and (v) Osimertinib (Tagrisso®). Osimertinib (Tagrisso®) is administered to subjects whose tumors are (EGFR) T790M-positive and whose disease has progressed on or after EGFR TKI therapy. In some embodiments, the administering angiogenesis inhibitor comprises administering to the subject of a therapeutic amount of Bevacizumab (Avastin®) and/or Ramucirumab (Cyramza®). In some embodiments, the immunotherapy comprises administering to the subject of a therapeutic amount of Nivolumab (Opdivo®), Pembrolizumab (Keytruda®), and/or Atezolizumab (Tecentriq®).

The identification of reliable predictive biomarkers and new therapeutic targets is a critical step for leading to real improvement in patient outcomes. To reach this purpose, we developed a multi-step bioinformatics analytic strategy to mine large omics data together with clinical data. A meta-analysis of transcriptome data identified 1327 genes significantly and robustly deregulated in lung adenocarcinomas (LuADCs) compared to normal lung tissue. 600 of these genes are significantly associated with overall survival (OS) of LuADC patients. The structure of a gene co-expression network revealed the biological functions of 600 genes in normal lung and LuADCs, which were enriched for cell cycle-related processes, blood vessel development, cell adhesion and metabolic processes. We established a 600 gene expression-based molecular classification of LuADCs into 4 possible subtypes, which is weakly, but significantly associated with OS in TCGA data. Finally, we implemented a multiple resampling method combined with a Cox regression analysis to identify a 27-gene signature associated with OS in the TCGA dataset, and then created a prognostic scoring system based on Cox regression function. This scoring system robustly predicts OS of LuADC patients in 100 sampling test sets and is further validated in four LuADC datasets. Our multi-omics and clinical data integration study identified a 27-gene prognostic signature that could guide adjuvant therapy for LuADC patients and includes novel potential molecular targets for therapy.

This invention is based on the discovery that: (1) a genome-wide screen identified 1327 genes significantly and robustly deregulated across four independent lung adenocarcinoma datasets compared to normal lung tissues; (2) the gene expression of 600 genes is significantly associated with overall survival (OS) in lung adenocarcinoma patients; (3) 4 molecular subtypes are identified based on the 600 genes associated with OS of patients with lung adenocarcinomas; (4) a forward-conditional Cox regression analysis identified a 27-gene signature associated with overall survival (OS) of lung adenocarcinomas; and, (5) a prognostic scoring system was created based on the 27-gene signature. This scoring system robustly predicted lung adenocarcinoma patient OS in 100 sampling test sets and was further validated in 4 independent lung tumor data sets. The 27-gene prognostic signature of the present invention is useful for guiding adjuvant therapy for lung cancer patients, including but not limited novel potential molecular targets for therapy.

The present invention is useful identifying genes important in lung cancer survival, so that novel targeted therapies can be developed, and for predicting lung cancer survival.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing aspects and others will be readily appreciated by the skilled artisan from the following description of illustrative embodiments when read in conjunction with the accompanying drawings.

FIG. 1. Human lung tissue data sets used in this study. Three independent gene transcript data sets containing LuADC and normal lung tissue samples were used. Differential expression of tumor versus normal using a fold-change cut-off of 5.0 and adjusted p-value<0.001 identified the 1982 common probe IDs consistently deregulated in all three datasets.

FIG. 2. Flow diagram for identifying and validating a prognostic biomarker panel for LuADC. (A) The 1982 robustly deregulated probe IDs represented 1327 genes of which 600 were significantly associated with LuADC overall survival used for functional analysis. (B) Kaplan-Meier survival curves for individual genes significantly associated with overall survival in LuADC patients. The LuADC patient cohort was divided into two equal groups based on median expression for each gene and compared by a Kaplan-Meier survival analysis. The estimate of the hazard ratio (HR) and log-rank p-value of the curve comparison between the groups is shown.

FIG. 3. Visual representation of Gene Ontology enrichment analysis of genes significantly associated with OS in LuADC. Functional enrichment analysis of the 600 genes significantly associated with OS was performed using ClueGo (p<0.001).

FIG. 4. Comparison network of gene correlations in normal lung and LuADC. (A) Gene-gene correlation networks for normal lung and LuADC were merged using DyNet. Nodes and/or edges present in both normal and tumor correlation networks are represented in white and gray, respectively. Nodes and/or edges present in either normal or tumor networks alone are represented in red and green, respectively. (B) Functional enrichment analysis of genes uniquely present in the normal lung correlation network (left) or the LuADC correlation network (red).

FIG. 5. A 27-gene signature is associated with OS in LuADC patients. (A) Cox regression was run on 100 random tumor samples for 600 genes significantly associated with OS to generate the 27-gene signature. The 27-gene signature was used to generate a prognostic scoring system, which was validated using 100 random test sets. (B) Kaplan-Meier overall survival curves for two representative test-cohorts separated into tertiles according to the prognostic score using the 27-gene signature. (C) For each of 100 test sets the HR and the 95% confidence interval was calculated using a Cox model based on the prognostic score with groups (good vs. poor: top; intermediate vs. poor: bottom). The red dotted line indicates a HR value of 1, or the null hypothesis. (D) Comparison of the HR for each of 100 test sets between the 27-gene signature and three existing gene signatures reported in the literature (REF).

FIG. 6. Independent validation of 27-gene signature. Kaplan-Meier overall survival curves were generated for four independent LuADC patient cohorts according to the prognostic score using the 27-gene signature. The patient cohort was divided into tertiles based on the prognostic score and the log-rank p-value of the curve comparison between the groups is shown. The hazard ratio and the 95% confidence interval was calculated using a Cox model based on tumor stage (I-IV), gender, age at diagnosis and prognostic score as covariates. Significant factors are highlighted in red.

FIG. 7. Expression architectures of 600 genes in normal lung (top) and LuADCs (below) are revealed by gene correlation network analysis. Gray edges indicate positive correlations and green edges indicate negative correlations.

FIG. 8. For each of three existing gene signatures, the HR and the 95% confidence interval were calculated for each test set using a Cox model based on the prognostic score with groups (intermediate vs. good: left; poor vs. good: right). The red line indicates a HR value of 1, or the null hypothesis.

DETAILED DESCRIPTION OF THE INVENTION

Before the invention is described in detail, it is to be understood that, unless otherwise indicated, this invention is not limited to particular sequences, expression vectors, enzymes, host microorganisms, or processes, as such may vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting.

In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings:

The terms “optional” or “optionally” as used herein mean that the subsequently described feature or structure may or may not be present, or that the subsequently described event or circumstance may or may not occur, and that the description includes instances where a particular feature or structure is present and instances where the feature or structure is absent, or instances where the event or circumstance occurs and instances where it does not.

As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to an “expression vector” includes a single expression vector as well as a plurality of expression vectors, either the same (e.g., the same operon) or different; reference to “cell” includes a single cell as well as a plurality of cells; and the like.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

The term “about” refers to a value including 10% more than the stated value and 10% less than the stated value.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

It is to be understood that, while the invention has been described in conjunction with the preferred specific embodiments thereof, the foregoing description is intended to illustrate and not limit the scope of the invention. Other aspects, advantages, and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

All patents, patent applications, and publications mentioned herein are hereby incorporated by reference in their entireties.

The invention having been described, the following examples are offered to illustrate the subject invention by way of illustration, not by way of limitation.

EXAMPLE 1
Identification of a Robust Gene Expression-Based Prognostic Risk Score to Predict Overall Survival of Lung Adenocarcinoma Patients

Identification of reliable predictive biomarkers and new therapeutic targets is a critical step for significant improvement in patient outcomes. Here, we developed a multi-step bioinformatics analytic strategy to mine large omics and clinical data to build a prognostic scoring system for predicting the overall survival (OS) of lung adenocarcinoma (LuADC) patients. In latter we first identified 1327 significantly and robustly deregulated genes, 600 of which were significantly associated with the OS of LuADC patients. Gene co-expression network analysis revealed the biological functions of these 600 genes in normal lung and LuADCs, which were found to be enriched for cell cycle-related processes, blood vessel development, cell-matrix adhesion and metabolic processes. Finally, we implemented a multiple resampling method combined with Cox regression analysis to identify a 27-gene signature associated with OS, and then created a prognostic scoring system based on this signature. This scoring system robustly predicted OS of LuADC patients in 100 sampling test sets and was further validated in four independent LuADC cohorts. In addition, in comparison to other existing prognostic gene signatures published in the literature, our signature was significantly superior in predicting OS of LuADC patients. In summary, our multi-omics and clinical data integration study created a 27-gene prognostic risk score that can predict OS of LuADC patients independent of age, gender and clinical stage. This score could guide therapeutic selection and allow stratification in clinical trials.

Herein is described a multi-step bioinformatics analytic strategy to mine large omics data together with clinical information to develop a gene expression-based prognostic risk score for lung adenocarcinomas (LuADCs). A resampling method is employed by splitting the LuADCs TCGA dataset into training and testing sets and then used repeated cross-validation to identify critical genes for prognostic classification. Based on these analyses, a 27-gene expression prognostic scoring system is created and successfully applied it to predict overall survival (OS) in multiple validation datasets. This study raises the prospect that the practicality of LuADC patient prognosis may be assessed by this prognostic scoring system.

Results

Identification of Consistently Deregulated Genes in Human LuADCs

A meta-analysis of three publically available LuADC transcriptome datasets (GSE31210, GSE19188 and GSE19804) was conducted to identify genes that are consistently deregulated in human LuADCs compared to normal lung tissues (FIG. 1). The significant differential expression of genes was assessed by a fold change cut-off of 5 and adjusted p-value<0.0001. This resulted in a set of 1982 probe IDs (1374 down-regulated and 608 up-regulated) represented by 1327 unique genes (884 down-regulated and 543 up-regulated), which were consistently deregulated in all three datasets (FIG. 1).

Impact of the Deregulated Genes on Overall Survival in Human LuADCs

To assess the importance of the 1327 deregulated genes in LuADC development, we evaluated their prognostic value for LuADC patients in a large public database combining tumor gene expression and patient survival¹⁷(FIG. 2, Panel A). The LuADC patient cohort was divided into two equal groups based on median expression for each gene. Subsequently, the effects of high or low expression levels on OS were examined using the Kaplan-Meier survival curve and log-rank test. This analysis identified 600 out of 1327 genes that were significantly associated with OS (adjusted p-value<0.05; FIG. 2, Panel B). 406 genes had a hazard ratio (HR)<1 (higher gene expression associated with good prognosis) and 194 genes had a HR>1 (higher gene expression associated with poor prognosis).

To reveal the molecular mechanism underlying LuADC development, we determined which Gene Ontology (GO) categories are statistically overrepresented in the 600 gene set, and observed significant enrichment for cell cycle, adhesion, cell death, angiogenesis, metabolism and kinase activity (FIG. 3), all of which are hallmarks of cancer.

Expression Architecture of Prognostic Genes in Normal Lung and LuADCs

Co-expression network analysis has been used to identify clusters of genes with common biological functionality important in normal or tumor tissues. We used data obtained from the GTEx database of 320 normal human lung tissues and the TCGA database of 517 LuADC samples to reveal the expression architecture of 600 OS-associated genes in normal lung and LuADC tissues. We first calculated correlation coefficients among 600 genes in both normal and LuADC tissue samples, and then constructed a gene co-expression network where nodes represent individual genes and edges connecting genes represent a significant correlation in expression (R≥|0.7|; adjusted p-value<0.001; FIG. 7). We then performed a comparison analysis between these two correlation networks by generating a composite network highlighting nodes and edges that were found exclusively in normal lung (red), exclusively in LuADC (green) or present in both (white) (FIG. 4, Panel A). This analysis revealed a shared co-expression clique enriched for cell cycle and mitosis genes and a second, larger, clique containing a sub-clique of genes co-expressed in normal lung (red) and genes co-expressed in LuADC (green). Gene Ontology analysis of these subcliques revealed significant enrichment for muscle growth, metabolism and cell-matrix adhesion in normal lung and endothelial cell differentiation and angiogenesis in LuADC (FIG. 4, Panel B).

Development of a Gene Expression Signature-Based Prognostic Risk Score in LuADC

We designed a strategy to develop a prognostic scoring system (FIG. 5, Panel A). We first used a resample method to split the TCGA dataset (total 517 patients) into 100 training (350 patients) and 100 testing (167 patients) datasets. We then performed a multivariate Cox regression analysis on all 100 training sets to discover statistically significant independent genes within the 600-gene set for predicting OS. The genes that recurred in at least 30% of 100 training sets were included in our final 27-gene signature (Table 1). A prognostic score for a patient was used to assess a patient's risk of death and was defined as the linear combination of logarithmically transformed gene expression levels weighted by average Cox regression co-efficient obtained from 100 training data sets (Table 2). The prognostic scores were assigned for all patients in both training and testing sets. In each training set, the patients were then divided into tertiles based on their prognostic score (good, intermediate and poor) and the prognostic score at the cut-points was recorded. Kaplan-Meier analysis was performed and a log-rank test was used to determine significant differences in OS among different groups for all training sets (FIG. 5, Panel B). The hazard ratio (HR) was calculated for each testing set for the “intermediate” and “poor” groups in comparison to the “good” group (FIG. 5, Panel C). In all test sets, patients in the “poor” group had a significant shorter OS than those in “good” group (HR confidence interval above “1”) (FIG. 5, Panel C, bottom panel), where in more than 70% of the test sets, patients in the “intermediate” group had a significant shorter OS than those in “good” group (FIG. 5, Panel C, top panel), indicating that this prognostic scoring system has discriminative ability to distinguish patients with good prognosis from patients with worse prognosis.

TABLE 1

Frequency of genes appeared in Cox regression model

among the 27 signature genes.

Gene name
Frequency

FAM83A
75

STK32A
72

TRPC6
70

DEFA1B
68

TMEM47
53

CDC25C
50

PRKAR2B
49

TMEM100
47

CNTN4
45

HOOK1
42

INPP5A
42

TRHDE
40

RSPO2
39

LDB3
36

SLC24A3
35

VEPH1
35

SLC1A1
34

GPM6A
33

TMEM106B
33

FOXP1
32

NTN4
32

PALD1
32

F12
31

FHL1
31

TIMP1
31

IGSF9
30

KLF9
30

TABLE 2

The average Cox regression co-efficient for each

gene is used to calculate prognostic score.

Gene Name
Cox regression co-efficient

FAM83A
0.20995771

STK32A
−0.45049286

TRPC6
0.382016798

DEFA1B
0.298967835

TMEM47
0.220892566

CDC25C
0.338527972

PRKAR2B
0.035274941

TMEM100
0.101858155

CNTN4
0.120687495

HOOK1
0.079775222

INPP5A
−0.220656803

TRHDE
0.363592887

RSPO2
0.092585398

LDB3
0.127095987

SLC24A3
−0.336677565

VEPH1
0.164080783

SLC1A1
0.192834044

GPM6A
0.086279146

TMEM106B
0.105899244

FOXP1
0.249725361

NTN4
0.159188986

PALD1
0.167148577

F12
0.158275055

FHL1
−0.869024553

TIMP1
0.14597252

IGSF9
0.078902808

KLF9
0.32007008

27-Gene Expression Signature-Based Prognostic Risk Score Independently Predicts Overall Survival in LuADC Patients

We then tested our 27-gene prognostic signature in four independent datasets of LuADC patients. Prognostic scores for all patients were calculated and patients were ranked based on their score and divided into three equal sized cohorts. Kaplan-Meier analysis revealed a significant difference among three patient cohorts. Patients with a high prognostic score had a significantly shorter OS compared to patients with a low prognostic score (p<0.001) in all datasets (FIG. 6, Panel A). Finally, we investigated whether our prognostic score was an independent prognostic factor over clinical information (age, gender and stage) using Cox regression. We conclude that our prognostic scores are independently and significantly associated with OS (FIG. 6, Panel B).

Comparison of 27-Gene Expression Signature with Existing Prognostic Signatures

There are a number of prognostic signatures for NSCLC prognosis in the literature. We compared the performance of three published signatures [12-14] with our 27-gene signature. For each of the published signatures, we performed a multivariate Cox regression analysis on the same 100 training sets, averaged the Cox regression co-efficient and calculated prognostic scores for all patients. For each signature, the patients were then divided into tertiles based on their prognostic scores and the prognostic scores at the cut-points were recorded. Finally, the HR was calculated for each testing set for the “intermediate” and “poor” groups in comparison to the “good” group (FIG. 8). The median HR of our 27-gene signature was on average 2.2-fold higher in the “intermediate” vs. “good” group and 5.0-fold higher in the “poor” vs “good” group compared to each of the three published signatures (FIG. 5, Panel D). We conclude that our signature was significantly superior in predicting OS of the LuADC patients.

Discussion

Lung cancer is the most common cancer and the leading cause of cancer death among both men and women worldwide [1,20]. NSCLC, like many other cancers, exhibits considerable complexity and heterogeneity in biology, drug response and survival [21], which represents a major obstacle to effective personalized treatment. This work aimed to identify reliable predictive biomarkers and build a prognostic scoring system for predicting OS of LuADC patients.

There are several prognostic signatures for NSCLC prognosis in the literature.^12-14While these signatures have been shown to predict lung cancer survival, they were developed based on a subset of all genes in the genome or were assembled based on existing knowledge on the role of genes in cancer. With the availability of lung cancer transcriptome data sets covering many additional genes it seemed plausible that that novel gene signatures better able to predict LuADC patient survival could exist. To this end, we embarked on a comprehensive and unbiased genome-wide screen for genes associated with lung cancer prognosis. We show that our 27-gene scoring system has robust discriminative ability to distinguish patients with good versus bad prognosis in multiple datasets independent of clinical characteristics including age, gender and pathological stage. A direct performance comparison of our signature with the three published signatures mentioned above in terms of predicting patient survival showed that, while all signatures were able to predict survival, our 27-gene signature was much more robust. To translate such findings into clinical practice, a multigene assay should be developed for further validation of this gene signature in assessment of LuADC survival. Such information will assist treatment decision-making in a way similar to that used for the Oncotype DX breast cancer assay developed by Genomic Health [9] and Mammaprint 70-gene breast cancer recurrence assay by Agendia [7]. Randomized prospective clinical trials to further validate the accuracy and clinical value of this novel prognostic test for LuADC patients will need to be conducted.

In conclusion, lung cancer remains the leading cause of cancer-related disease burden. We developed a multi-step unbiased bioinformatics analytic approach to identify reliable predictive biomarkers and new therapeutic targets for LuADCs. We discovered that the expression of 600 genes are consistently altered in LUADCs and are significantly associated with OS of LuADC patients. Our study created a robust 27-gene prognostic signature that could predict patient overall survival independent of age, gender and clinical stage. This signature could guide adjuvant therapy for LuADC patients and include novel potential molecular targets for therapy.

Materials and Methods

Data Sets Used in this Study

Gene transcript data of normal and LuADC tissues was obtained from NCBI Gene Expression Omnibus (GEO) accession numbers: GSE31210, GSE19188 and GSE19804. Normal lung gene transcript data used for generating gene expression correlation networks were obtained from GTEx (website for: gtexportal.org/home/datasets) using the RPKM normalized gene transcript counts table [15,16].

Statistical Analysis

GEO2R was used to calculate the differential expression of tumor versus normal using a fold-change cut-off of 5 and adjusted p-value<0.0001. Association of differentially expressed genes and OS in LuADC patients was assessed using Kaplan-Meier plotter (website for: kmplot.com) including KM survival analysis, hazard ratio (HR) with 95% confidence intervals and logrank p-value for each gene [17]. The cytoscape plugin ClueGO was used to assess overrepresentation of Gene Ontology categories in biological networks (adjusted p<0.001 was used as a threshold for significance) [18].

Gene Co-Expression Network Construction

Gene expression Spearman correlation coefficients were calculated in “R” for 600 genes that were differentially expressed between LuADC and normal tissues samples and significantly associated with OS of LuADC patients. A gene network was generated where nodes represent individual genes and edges connecting nodes were drawn when the correlation coefficient exceeded R≥|0.7| (adjusted p-value≤0.001). Gene co-expression networks were generated for normal lung gene expression data (GTEx) and lung adenocarcinoma (TCGA) and visualized using Cytoscape 3.4.0. (website for: cytoscape.org). Dynet was used to highlight differences between two networks based on node and edge presence, ClueGO was used to identify significantly enriched biological pathways [18,19].

Gene Expression Signature-Based Prognostic Risk Score

100 random selections of 350 patients with LuADC were extracted from TCGA dataset and used as a training set to isolate a biomarker panel associated with OS. The remaining 167 patients for each selection were used as a test set to validate the prognostic significance of the biomarker panel. A forward-conditional Cox regression using all 600 genes as covariates was performed using SPSS on each of the training sets in order to isolate the biomarker panel. The results of each test were recorded and the genes that appeared in more than half of the training sets were included in our biomarker panel.

Cox regression was repeated on all 100 training sets using our 27-gene signature as covariates using the forced-entry (enter) method to obtain the co-efficient values for each biomarker. The resulting 100 co-efficient values of each biomarker were averaged to estimate the true co-efficient value of each gene. A prognostic scoring system was created based on this formula:

$\sum_{i = 1}^{12} (gene i co - efficient) \times (gene i expression level)$

The patients were ranked by their prognostic scores and divided into three equal sized cohorts. Kaplan-Meier plots were constructed and a long-rank test was used to determine differences in OS of LuADC patients.

Prognostic scores for each of the test set samples were then calculated using the same set of mean co-efficient values developed in the training set. Patients were ranked based on their prognostic scores and divided into three cohorts based on the average prognostic score at cut-point in the training sets. Kaplan-Meier plots were constructed and a long-rank test was used to determine differences among OS in all testing sets.

To further validate our biomarker panel, mRNA expression levels for the 27-gene signature were obtained from four additional datasets (GSE42127, GSE31210, GSE37745 and GSE30219). New coefficients for 27 genes were obtained from Cox regression. Prognostic scores for all patients were calculated and patients were ranked based on their scores and divided into three equal sized cohorts. Kaplan-Meier analysis and a long-rank test were used to determine differences in survival.

REFERENCES CITED

1. Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015; 65: 5-29.

2. Miller K D, Siegel R L, Lin C C, Mariotto A B, Kramer J L, Rowland J H, Stein K D, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians. 2016; 66: 271-89.

3. Lynch T J, Bell D W, Sordella R, Gurubhagavatula S, Okimoto R A, Brannigan B W, Harris P L, Haserlat S M, Supko J G, Haluska F G, Louis D N, Christiani D C, Settleman J, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine. 2004; 350: 2129-239.

4. Matsubura D, Morikawa T, Goto A, Nakajima J, Fukayama M, Niki T. Subepithelial myofibroblast in lung adenocarcinoma: a histological indicator of excellent prognosis. Modern Pathology. 2009; 22: 776-785.

5. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna J D, Lee J J, Kim E, Hong W K, Wistuba II, Lotan R. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clinical Cancer Research. 2010; 17: 1490-501.

6. Graziano S L, Gamble G P, Newman N B, Abbott L Z, Rooney M, Mookherjee S, Lamb M L, Kohman L J, Poiesz B J. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. Journal of Clinical Oncology. 1999; 17: 668-75.

7. Cardoso F, van't Veer L J, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga J Y, Brain E, Causeret S, DeLorenzi M, Glas A M, Golfinopoulos V, Goulioti T, et al. 70-Gene signature as an aid to treatment Decisions in early-stage breast cancer. New England Journal of Medicine. 2016; 375: 717-29.

8. Gray R G, Quirke P, Handley K, Lopatin M, Magill L, Baehner F L, Beaumont C, Clark-Langone K M, Yoshizawa C N, Lee M, Watson D, Shak S, Kerr D J. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. Journal of Clinical Oncology. 2011; 29: 4611-9.

9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner F L, Walker M G, Watson D, Park T, Hiller W, Fisher E R, Wickerham D L, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine. 2004; 351: 2817-26.

10. Wang P, Wang Y, Hang B, Zou X, Mao J H. A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget. 2016; 7:55343-51.

11. Atwater T, Massion P P. Biomarkers of risk to develop lung cancer in the new screening era. Ann Transl Med. 2016; 4: 158.

12. Zhu C Q, Ding K, Strumpf D, Weir B A, Meyerson M, Pennell N, Thomas R K, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. Journal of Clinical Oncology. 2010; 28: 4417-24.

13. Kratz J R, He J, Van Den Eeden S K, Zhu Z H, Gao W, Pham P T, Mulvihill M S, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry C P, Habel L A, et al. A practical molecular assay to predict survival in resected non-squamous, non-small cell lung cancer: development and international validation studies. Lancet. 2012; 379: 823-32.

14. Wistuba I I, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso M G, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher S G, et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clinical Cancer Research. 2013; 19: 6261-71.

15. Consortium G T. The Genotype-Tissue Expression (GTEx) project. Nature Genet. 2015; 45:580-5.

16. Mele M, Ferreira P G, Reverter F, DeLuca D S, Monlong J, Sammeth M, Young T R, Goldmann J M, Pervouchine D D, Sullivan T J, Johnson R, Segrè A V, Djebali S, et al. Human genomics. The human transcriptome across tissues and individuals. Science. 2015; 348: 660-5.

17. Gyorffy B, Surowiak P, Budczies J, Lánczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer, PLoS One. 2013; 8: e82241.

18. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman W H, Pages F, Trajanoski Z, Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25:1091-3.

19. Goenawan I H, Bryan K, Lynn D J. DyNet: visualization and analysis of dynamic molecular interaction networks. Bioinformatics. 2016; 32: 2713-5.

20. Chen W, Zheng R, Baade P D, Zhang S, Zeng H, Bray F, Jemal A, Yu X Q, He J. Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016; 66: 115-32.

21. Chen Z, Fillmore C M, Hammerman P S, Kim C F, Wong K K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nature Reviews Cancer. 2014; 14: 535-46.

While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

Novel set of biomarkers useful for predicting lung cancer survival

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

RELATED PATENT APPLICATIONS

STATEMENT OF GOVERNMENTAL SUPPORT

Provisional Applications (1)